News

New Hope for Chronic Stroke Patients

Cerebrolysin® strongly improves impairment after stroke!
read more

Advances in the treatment of TBI and stroke

Detailed IMMM Report now available!
read more
1 … 49 50 51 52 53 … 68
03.04.2025

Cerebrolysin® as an Adjuvant Therapy After Mechanical Thrombectomy in Cardioembolic Stroke

Does Cerebrolysin® increase the safety and efficacy after mechanical thrombectomy?
Read more
1 … 34
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.